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Background. Case fatality rates among hospitalized patients diagnosed with human immunodeficiency virus (HIV)-associated 
tuberculosis remain high, and tuberculosis mycobacteremia is common. Our aim was to define the nature of innate immune 
responses associated with 12-week mortality in this population.
Methods. This prospective cohort study was conducted at Khayelitsha Hospital, Cape Town, South Africa. Hospitalized HIV-
infected tuberculosis patients with CD4 counts <350 cells/µL were included; tuberculosis blood cultures were performed in all. 
Ambulatory HIV-infected patients without active tuberculosis were recruited as controls. Whole blood was stimulated with Escherichia 
coli derived lipopolysaccharide, heat-killed Streptococcus pneumoniae, and Mycobacterium tuberculosis. Biomarkers of inflammation 
and sepsis, intracellular (flow cytometry) and secreted cytokines (Luminex), were assessed for associations with 12-week mortality using 
Cox proportional hazard models. Second, we investigated associations of these immune markers with tuberculosis mycobacteremia.
Results. Sixty patients were included (median CD4 count 53 cells/µL (interquartile range [IQR], 22–132); 16 (27%) died after a 
median of 12 (IQR, 0–24) days. Thirty-one (52%) grew M. tuberculosis on blood culture. Mortality was associated with higher concen-
trations of procalcitonin, activation of the innate immune system (% CD16+CD14+ monocytes, interleukin-6, tumour necrosis factor-ɑ 
and colony-stimulating factor 3), and antiinflammatory markers (increased interleukin-1 receptor antagonist and lower monocyte and 
neutrophil responses to bacterial stimuli). Tuberculosis mycobacteremia was not associated with mortality, nor with biomarkers of sepsis.
Conclusions. Twelve-week mortality was associated with greater pro- and antiinflammatory alterations of the innate immune 
system, similar to those reported in severe bacterial sepsis.
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Tuberculosis remains the most frequent cause of hospitalization 
and death in human immunodeficiency virus (HIV)-infected 
patients [1]. Mortality is particularly high among HIV-infected 
patients who start tuberculosis treatment while in the hospital, 
ranging from 6% to 32% [2].
The causes of this high mortality (despite receiving tuber-
culosis treatment) are not well defined. Post-mortem exami-
nations report disseminated tuberculosis as a primary cause 
of death in many HIV-infected persons [3, 4]. However, tuber-
culosis mycobacteremia, which is a frequent finding in febrile 
HIV-infected inpatients [5, 6], has not been consistently associ-
ated with mortality [5, 7, 8].
Although there is no published literature to date on immu-
nological changes that accompany mycobacteremia, bacterial 
sepsis has been studied extensively. Bacterial sepsis is charac-
terized by imbalanced host responses with both proinflamma-
tory and immune suppressive features [9], including monocyte 
deactivation, neutrophil dysfunction, and increased production 
of interleukin (IL)-10 [10], potentially contributing to a height-
ened risk for secondary infections [9, 11].
In HIV-associated tuberculosis (HIV-tuberculosis), simi-
lar changes have been described. Reduced innate responses 
upon stimulation in vitro with lipopolysaccharide (LPS) and 
heat-killed Mycobacterium tuberculosis (Mtb) have been asso-
ciated with death and poor outcome [12], and failure of cel-
lular immune recovery has been associated with death after 
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antiretroviral therapy (ART) initiation in tuberculosis patients 
[13, 14].
We hypothesized that hospitalized HIV-tuberculosis patients, 
compared with HIV-infected outpatients without tuberculo-
sis (controls), would have elevation of sepsis biomarkers and 
proinflammatory cytokines as well as evidence of increased 
antiinflammatory signalling and decreased innate immune 
responses to bacterial stimuli and that these features would 
be associated with mortality. Second, we hypothesized that 
tuberculosis mycobacteremia would be associated with these 
immunological features and mortality. Additionally, we tested 
whether ex vivo treatment with recombinant interferon (IFN)-ɣ 
(a potential host-directed therapy) could restore monocyte 
responses to LPS.
METHODS
Study Design and Population
We conducted a prospective cohort study in Khayelitsha, Cape 
Town, South Africa. Khayelitsha has a tuberculosis notification 
rate of 1065/100 000 person-years (City of Cape Town, unpub-
lished data) and antenatal HIV seroprevalence of 34% [15].
Nonpregnant HIV-infected patients with CD4 counts <350 
cells/µL and diagnosed with tuberculosis on admission to 
Khayelitsha Hospital were recruited between June 2014 and 
October 2014. Patients were excluded if they were transfused or 
had received more than 1 dose of tuberculosis treatment within 
the preceding month. Patients with microbiologically proven 
rifampicin-susceptible tuberculosis were included. Selection 
bias was minimized by using a random selection procedure.
HIV-infected outpatients with CD4 counts <350 cells/µL 
without active tuberculosis were recruited at Úbuntu Clinic, 
Khayelitsha, Cape Town (controls). To ensure more appropriate 
matching, only control patients with CD4 counts <150 cells/µL 
were included in the final analyses.
Outcomes and Definitions
We aimed to determine immunologic changes associated with 
the primary outcome of 12-week mortality. Second, we assessed 
associations of tuberculosis mycobacteremia, defined as at least 
1 MycoFlytic blood culture growing Mtb, with immunologic 
profile and outcome. Sepsis definitions were adapted from pub-
lished criteria (Supplementary Table 1) [9].
Procedures
A detailed description of ethical aspects and data collection is 
provided in the Supplementary Methods. All participants had 
the following tests performed: Xpert MTB/RIF (Mycobacterium 
tuberculosis/rifampin) assay on sputum and urine, tuberculosis 
culture on sputum, chest X ray, full blood count and differential, 
chemistry, HIV viral load, and CD4 count. MycoFlytic blood 
cultures were performed for hospitalized patients. Control 
patients were excluded if a tuberculosis symptom screen or any 
tuberculosis diagnostic test was positive. Hospitalized patients 
were contacted by telephone at 4 weeks and clinically reviewed 
at 12 weeks.
Whole blood was stimulated for 6 hours. Anti-(myco-)bac-
terial responses were tested using Escherichia coli–derived LPS, 
heat-killed Streptococcus pneumoniae, and heat-killed Mtb 
strain H37Rv. The ex vivo effect of IFN-ɣ was assessed in a 
costimulation assay with LPS.
Samples were stained with surface and intracellular mark-
ers (Supplementary Table  2) and acquired on a BD LSR 
Fortessa Flow Cytometer. Data were analyzed in FlowJo, ver-
sion 10 (Ashland, Oregon). Gating strategies are illustrated 
in Supplementary Figure  1. Concentrations of 12 cytokines 
(Supplementary Table  2) were measured in culture superna-
tants using a Luminex multiplex assay.
Statistical Analyses
Data were analyzed using SPSS, version 22 (IBM, Chicago, 
Illinois); GraphPad PRISM, version 6 (San Diego, California); 
and R (Vienna, Austria).
Medians were compared among groups using the appropri-
ate statistical test. Variables were investigated for associations 
with mortality in a Cox proportional hazards model. A priori–
defined potential confounders were age, sex, ART status, HIV 
viral load and CD4 count, and Luminex plate number; a var-
iable was retained in the model if introduction led to a >10% 
change in the effect measure.
All reported q values were calculated using Benjamini-
Hochberg procedures for multiple-testing correction [16]. 
P values < .05 and q values <.10 were regarded as significant.
Patients for whom data were available for all stimulation con-
ditions were included (n = 37) for principal component analysis 
(PCA); 90 variables were included per patient. Using a Shapiro 
test, all variables with P < .05 were log-transformed, and scaling 
was done. Data missing due to technical difficulties (112/3300 val-
ues; 3.4%) were imputed using the K-nearest-neighbor technique.
RESULTS
Participants
Of 124 HIV-infected patients with probable tuberculosis 
who were enrolled, 60 participants with confirmed rifampic-
in-susceptible tuberculosis were included in this analysis. 
Twenty-seven HIV-infected control patients were included 
(Supplementary Figure  2). All HIV-tuberculosis patients ful-
filled criteria for sepsis; 38/60 (63.3%) had severe sepsis and 
23/60 (38.3%) had septic shock (Table  1). Tuberculosis treat-
ment was initiated in all patients a median of 1 day (interquartile 
range [IQR], 0.5–2.5  days) after recruitment. Co-trimoxazole 
prophylaxis was initiated in the hospital in 28 (46.7%) patients, 
and 54 (90.0%) received broad-spectrum antibiotics (mostly 
ceftriaxone). Most patients were on ART at enrollment (31/60, 
52%; Table 1).
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Clinical Presentation and Outcomes
Compared with controls, HIV-tuberculosis patients had higher 
HIV viral loads and were more often anaemic (Table 1). Also, 
35/41 (85%) HIV-tuberculosis patients who could produce 
sputum had a positive sputum Xpert MTB/RIF or culture for 
Mtb; 31/60 (52%) patients grew Mtb on blood culture; 15/35 
(43%) had a positive urine Xpert MTB/RIF; and 16 patients had 
positive cultures or Xpert MTB/RIF from other sites. In addi-
tion, 28/60 (47%) patients had standard bacterial blood cultures 
performed prior to receipt of broad-spectrum antibiotics; none 
grew pathologic bacteria. By 12 weeks, 16 HIV-tuberculosis 
patients had died (26.7%) a median of 12 (IQR, 0–24) days 
after enrollment (Supplementary Table  3); none were lost to 
follow-up. All deaths occurred while the patients were in the 
hospital. Four patients had suspected bacterial sepsis when they 
died, and 11 deaths were attributed to disseminated tuberculo-
sis; 1 of them had disseminated tuberculosis and features that 
suggested bacterial sepsis.
Compared with HIV-tuberculosis patients who survived, 
patients who died were older and presented more often with 
severe sepsis or septic shock (Table  1). Mycobacteremia was 
not associated with mortality (crude hazard ratio [cHR], 0.74; 
95% confidence interval [CI], 0.3–2.0; and P  =  .55; adjusted 
HR [aHR], 0.80; 95% CI, 0.3–2.2; and P =  .64), nor was time 
to tuberculosis treatment in days (cHR, 0.87; 95% CI, 0.69–
1.11; and P = .26; aHR, 0.82; 95% CI, 0.63–1.07; and P = .14). 
Table 1. Clinical Characteristics and Hematology and Chemistry Results
Variables
HIV + Tuberculosis 
Controls (n = 14)
HIV + Tuberculosis 
Patients (n = 60) q Valuea
Survivors  
(n = 44)
Deceased  
(n = 16) q Valueb
Demographics
Male sex (n, %) 4/14 (29) 30/60 (50) 0.21 24/44 (55) 6/16 (38) 0.22
Age 34 (29–42) 39 (33–45) 0.25 36 (31–41) 44 (35–55) 0.09
ART status (n, %)
Naive 8/14 (57) 31/60 (52) 0.79 25/43 (57) 6/16 (38) 0.35
On ART 1/14 (7) 16/60 (27) 11/43 (25) 5/16 (31)
Defaulted 5/14 (36) 12/60 (20) 7/43 (16) 5/16 (31)
HIV disease markers
CD4 count (cells/µL) 71 (56–121) 53 (22–132) 0.26 57 (22–139) 45 (19–90) 0.63
HIV VL (log) 4.55 (2.16–5.29) 5.62 (3.97–6.08) 0.02 5.68 (4.85–6.16) 4.39 (3.18–5.69) 0.17
HIV VL undetectable (n, %) 3 (21) 5 (8.3) 0.19 3 (6.8) 2 (12.5) 0.48
Tuberculosis diagnostics
Sputum culture/Xpert positive 
(n, %)
0/14 (0) 35/41 (85) 0.0002 26/31 (84) 9/10 (90) 0.69
Urine Xpert positive (n, %) 0/14 (0) 15/35 (43) 0.0002 9/26 (35) 6/9 (66) 0.22
Tuberculosis blood culture 
positive (n, %)
ND 31/60 (52) 24/44 (55) 7/16 (44) 0.60
Sepsis criteria
Sepsis (n, %) 0/14 (0) 60/60 (100) 0.0002 44/44 (100) 16/16 (100) ND
Severe sepsis (n, %) 0/14 (0) 39/60 (65) 0.0002 26/44 (59.1) 13/16 (81.3) 0.22
Septic shock (n, %) 0/14 (0) 23/60 (38) 0.0002 14/44 (31.8) 9/16 (56.3) 0.22
Hematology
Hemoglobin (g/dL) 12.0 (10.1–12.9) 8.9 (6.7–10.8) 0.002 9.3 (7.0–11.4) 6.9 (6.4–9.8) 0.22
White cell count (109/L) 3.7 (2.9–4.5) 6.4 (4.4–9.4) 0.0002 7.0 (4.8–10.4) 5.8 (3.9–7.6) 0.22
Neutrophils (109/L) 1.2 (1.3–2.5) 5.8 (3.6–9.3) 0.0002 6.0 (4.2–9.5) 4.7 (2.7–6.8) 0.22
Lymphocytes (109/L) 1.00 (0.88–1.43) 0.56 (0.36–0.96) 0.002 0.58 (0.37–1.03) 0.49 (0.29–0.78) 0.31
Monocytes (109/L) 0.36 (0.33–0.42) 0.33 (0.16–0.51) 0.53 0.39 (0.19–0.58) 0.20 (0.12–0.43) 0.22
Platelets (109/L) 220 (192–316) 251 (179–325) 0.75 250 (183–325) 259 (119–330) 0.78
Serum chemistry
Glucose (mmol/L) ND 5.3 (4.9–6.5) ND 5.3 (5.0–6.2) 5.5 (3.9–7.8) 0.86
Lactate (mmol/L) ND 1.9 (1.3–3.0) ND 1.8 (1.2–2.6) 2.7 (1.5–3.8) 0.22
Procalcitonin (μg/L) ND 2.42 (0.54–8.67) ND 1.31 (0.36–4.98) 8.28 (3.63–61.05) 0.07
C-reactive protein (mg/L) ND 143 (94–191) ND 139 (83–191) 143 (129–230) 0.39
Albumin (g/L) ND 23 (19–28) ND 25 (19–28) 20 (17–24) 0.15
Creatinine (µmol/L) ND 90 (49–131) ND 84 (60–139) 105 (61–195) 0.63
χ2 tests were used for categorical data, Student t test for normally distributed continuous data, and Mann-Whitney U tests for nonnormally distributed data. Medians and interquartile ranges 
are shown for all variables, unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; ND, not determined; VL, viral load.
aq value of comparisons between the HIV-infected control group and HIV-associated tuberculosis patients. Significant differences (q < .10) are in bold.
bq value of comparisons between the group of patients who died and the group who survived. Significant differences (q < .10) are in bold.
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HIV-tuberculosis patients who died had significantly higher 
concentrations of procalcitonin compared with survivors 
(Table 1).
Immune Phenotype in HIV-Tuberculosis Versus Controls
In unstimulated samples, patients with HIV-tuberculosis had 
higher percentages of tumor necrosis factor (TNF)-α+ monocytes 
compared with controls (Figure 1) and higher supernatant concen-
trations of colony-stimulating factor (CSF)-3 and IFN-ɣ, whereas 
supernatant concentrations of IL-1β and IL-8 were lower (Table 2).
Whole blood of HIV-tuberculosis patients showed a 
significantly reduced production of proinflammatory 
cytokines following stimulation compared with controls 
(Figure  1, Table  2). In response to LPS, percentages of 
IL-6+ and TNF-α+ monocytes were lower (Figure  1), 
as were percentages of IL-6+ and TNF-α+ neutrophils 
(q = 0.003, q = 0.003, respectively) and supernatant con-
centrations of CSF-2 and proinflammatory cytokines 
IL-12p40, IL-1β, IL-6, IL-8, and TNF-α (Table  2). 
Supernatant IFN-ɣ and antiinflammatory IL1-RA 
Figure 1. Monocyte responses and mortality. Median values and interquartile ranges are shown for the percentage of CD16+ monocytes in unstimulated samples (human 
immunodeficiency virus [HIV] controls, n = 26; HIV-tuberculosis patients, n = 55) (A), and percentages (B) and absolute counts (C) of interleukin-6+ and tumor necrosis fac-
tor-ɑ+ monocytes in response to lipopolysaccharide (HIV controls, n = 25; HIV-tuberculosis patients, n = 55), Streptococcus pneumoniae (HIV controls, n = 25; HIV-tuberculosis 
patients, n = 31), and Mycobacterium tuberculosis (HIV controls, n = 26; HIV-tuberculosis patients, n = 47) respective stimulants. Absolute counts were derived by multiplying 
the percentage of positive cells by the monocyte count obtained from the National Health Laboratory Service clinical laboratory. HIV-infected control patients (black circles), 
HIV-tuberculosis patients who survived (blue triangles), and HIV-tuberculosis patients who died (red squares) are shown. Kruskal-Wallis and Mann-Whitney U tests were 
used for comparisons between groups. *P < .05, **P < .01, *** P < .001, ****P < .0001. Abbreviations: HIV, human immunodeficiency virus; IL, interleukin; LPS, lipopolysac-
charide; Mtb, heat-killed Mycobacterium tuberculosis; S. pneumoniae, Streptococcus pneumoniae; TNF, tumour necrosis factor; US, unstimulated.
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Table 2. Cytokine Concentrations in Culture Supernatants
HIV + Tuberculosis Controls HIV + Tuberculosis Patients
q Valuea
HIV + Tuberculosis Deceased HIV + Tuberculosis Survived
q Valueb
Cytokine Median
IQR
Median
IQR
Median
IQR
Median
IQRUnstimulated n = 14 n = 60 n = 16 n = 44
CSF-3 51 39.78–86.03 77 52.4–163.5 0.04 134.7 75.3–341.8 66.86 48.6–143.9 0.09
CSF-2 14 10.65–18.82 12 10.5–13.7 0.30 11.69 10.7–14.2 12.01 10.4–13.7 1.00
IFN-A2 15 10.97–20.00 14 10.9–18.4 0.66 13.41 11.7–18.1 14.07 10.1–19.1 0.99
IFN-ɣ 45 16.36–74.39 92 39.7–249.4 0.02 168.5 81.5–246.6 72.73 35.1–269.6 0.49
IL-10 23 14.77–34.57 24 14.9–29.6 0.96 25.91 14.4–62.6 23.11 14.9–27.7 0.61
IL-12p40 21 13.84–31.33 20 16.3–23.7 0.82 21.03 14.7–27.0 19.57 16.3–23.5 0.76
IL-1RA 151 83.78–212.6 252 109.2–495.3 0.14 566.7 130.2–958.6 241.9 107.2–423.8 0.30
IL-1β 6 3.75–29.79 3 2.4–4.7 0.01 3.19 2.5–4.4 3.14 2.34–5.0 0.93
IL-6 91 34.59–442.9 50 24.4–106.8 0.16 55 41.3–128.2 45.09 20.4–90.8 0.35
IL-8 1826 922.5–4095 619 276.8–1563 0.01 579.4 279–1314 658.8 220.1–1781 0.89
TNF-α 111 69.52–291.7 93 62.7–153.9 0.48 125.1 72.7–202 88.18 54.9–137.2 0.30
LPS n = 14 n = 60 n = 16 n = 44
CSF-3 363 259.5–514.8 393 206.1–614.0 0.89 439.5 227.6–1235 370.6 202.8–557.3 0.66
CSF-2 18 12.46–23.33 13 11.4–14.8 0.02 12.69 11.4–15.4 13.28 11.4–14.8 0.79
IFN-A2 16 14.30–24.19 15 11.9–19.1 0.31 14.63 11.9–17.6 14.94 11.7–20.8 0.93
IFN-ɣ 38 29.85–74 87 51.3–217.4 0.02 160.2 83.6–229.4 76.97 44.4–212 0.31
IL-10 236 199.9–493 225 83.2–445.2 0.50 170.9 65.4–341.1 236 112.9–635.3 0.31
IL-12p40 130 63.49–274 38 25.2–82.8 0.01 33.82 23.5–71.5 42.07 25.8–89.0 0.61
IL-1RA 768 388.5–1511 2219 993.7–4478 0.01 1961 500–4498 2302 1137–4607 0.66
IL-1β 2740 1772–4494 337 61.2–1024 0.0001 149.6 43.3–451 416.3 89.3–1102 0.24
IL-6 10432 3015–12118 7860 2664–9437 0.07 2941 1829–9386 8372 3442–9475 0.31
IL-8 7229 3150–9331 4079 1788–9546 0.29 3229 1778–9309 4891 1793–9684 0.76
TNF-α 7452 3634–10339 1669 823.4–4490 0.01 1197 589.6–2734 2506 961.6–5070 0.21
Streptococcus 
pneumoniae
n = 14 n = 37 n = 11 n = 26
CSF-3 81 65–122 149 88.1–240.6 0.04 237.5 138.0–483.5 103 78.1–171 0.08
CSF-2 21 14–27 13 11.4–14.8 0.0001 12.69 9.7–13.3 12.69 11.5–14.9 0.76
IFN-A2 16 12--21 14 11.5–19.4 0.50 13.76 12.5–22.5 13.64 11.0–18.6 0.81
IFN-ɣ 35 25–82 118 49.6–211.0 0.02 150.3 56.5–182.5 97.6 45.9–224.3 0.80
IL-10 39 32–102 41 25.3–72.2 0.77 34.88 21.3–76.8 42.75 25.7–63.8 0.89
IL-12p40 43 27–60 25 19.9–35.0 0.04 25.44 18.2–30.0 25.53 20.7–37.7 0.76
IL-1RA 422 168–488 801 499.3–1880 0.0001 1030 424.2–3361 786.9 522.3–1789 0.76
IL-1β 955 786–1252 131 21.2–265.6 0.0001 20.55 9.3–61.5 152 47.7–311.5 0.08
IL-6 7491 2114–8801 1581 339.5–3673 0.01 834.6 169.6–1586 2031 409.5–4748 0.08
IL-8 10000 3544–12138 9067 2890–11003 0.52 4028 1394–10033 9415 4394–11286 0.35
TNF-α 5158 2965–7742 1270 480.0–3063 0.01 488.2 248.8–1021 2074 750.7–3263 0.20
Mycobacterium 
tuberculosis
n = 14 n = 54 n = 14 n = 40
CSF-3 107 64–275 404 178.4–902.1 0.01 383.1 305.9–924.2 445 135.4–929.1 0.89
CSF-2 32 23–45 21 13.6–32.3 0.10 17.73 12.7–20.8 23.61 14.4–39.3 0.21
IFN-A2 16 13–21 15 12.2–19.9 0.42 14.6 12.0–19.2 14.74 12.3–20.5 0.89
IFN-ɣ 37 18–68 138 55.2–289.0 0.01 149.7 62.2–226.1 119.2 54.5–293.3 0.96
IL-10 125 61–194 93 47.4–306.9 0.93 54.45 44.2–148.4 104.8 62.9–365.8 0.30
IL-12p40 28 17–42 25 17.5–37.2 0.89 22.32 16.3–30.1 25.94 18.1–38.7 0.49
IL-1RA 295 139–554 844 315.7–1517 0.01 1051 192.9–2238 816.9 369.9–1448 0.96
IL-1β 705 389–1305 415 48.6–1203 0.48 202.9 29.6–411.2 686.4 67.8–2329 0.19
IL-6 5744 2441–7976 5848 1528–10229 0.77 1972 1097–8467 7954 2044–10663 0.26
IL-8 9121 2805–11520 9303 3516–11278 0.73 8351 5566–10254 9798 3430–11789 0.66
TNF-α 2103 1508–3971 2296 755.0–6655 0.74 1153 548.6–2473 2793 844.6–8411 0.20
Median and IQRs of cytokine concentrations measured in culture supernatants of HIV-infected control patients, HIV-tuberculosis survivors, and HIV-tuberculosis nonsurvivors, respectively. 
Values are in picogram per milliliter. Mann-Whitney U tests were used for nonparametric data and Student T tests for parametric data.
Abbreviations: CSF, colony-stimulating factor; HIV, human immunodeficiency virus; IFN, interferon; IL, interleukin; IQR, interquartile range; LPS, lipopolysaccharide; TNF, tumour necrosis factor. 
aq value of comparisons between the HIV-infected control group and HIV-associated tuberculosis patients. Significant differences (q < .10) are in bold.
bq value of comparisons between the group of patients who died and the group of patients who survived. Significant differences (q < .10) are in bold.
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concentrations were higher in HIV-tuberculosis patients 
(Table 2).
In S. pneumoniae stimulations, percentages of IL-6+ and 
TNF-α+ monocyte counts (q = 0.003) and IL-6+ absolute mono-
cyte (q = 0.003) counts were lower in HIV-tuberculosis patients 
(Figure 1), as were percentages and absolute counts of IL-6+ (q 
= 0.003) and TNF-α+ (q = 0.01) neutrophils. HIV-tuberculosis 
patients had higher supernatant concentrations of CSF-3, IFN-
ɣ, and IL-1-receptor-antagonist (IL-1RA) and lower concentra-
tions of CSF-2, IL-12p40, IL-1β, IL-6, and TNF-α (Table 2).
In Mtb stimulations, percentages and absolute counts of 
IL-6+ and TNF-α+ monocytes were similar in HIV-tuberculosis 
patients and controls (Figure  1). Percentages of IL-6+ and 
TNF-α+ neutrophils were lower in HIV-tuberculosis patients 
(q = 0.01 and q = 0.07, respectively), whereas concentrations of 
CSF-3, IFN-ɣ, and IL-1RA were higher (Table 2).
Pro- and Antiinflammatory Changes in Hospitalized HIV-Tuberculosis 
Patients Who Died Versus Survivors
Immune activation was associated with mortality. Patients 
who died had higher percentages of CD16+CD14+ monocytes 
and higher supernatant concentrations of CSF-3 in unstimu-
lated samples compared with patients who survived (Figure 1, 
Table 2). Higher percentages of activated CD16+CD14+ mono-
cytes (Figure 2A) were independently associated with mortality, 
as were supernatant concentrations of CSF-3, IL-1RA, IL-6, and 
TNF-α (Figure 2).
Compared with survivors, patients who died had lower 
absolute counts of IL-6+ and TNF-α+ producing monocytes in 
response to LPS and S.  pneumoniae (Figure  1). Lower super-
natant IL-1β and IL-6 concentrations and higher CSF-3 con-
centrations were measured in S.  pneumoniae stimulations of 
patients who died (Table  2). Impaired monocyte and TNF-α 
and IL-6 production in response to S. pneumoniae and lower 
percentages of IL-6+ neutrophils in response to LPS were inde-
pendently associated with mortality (Figure  2A, Figure  3), as 
were increased supernatant concentrations of CSF-3 and lower 
concentrations of IL-1β and TNF-ɑ in response to S. pneumo-
niae (Figure 2B).
In response to heat-killed Mtb, patients who died had 
lower absolute counts of IL-6+ and TNF-ɑ+ neutrophils. 
No differences were seen in Mtb culture supernatants 
(Table 2). Mtb responses were not associated with mortality 
(Figure 2).
In PCA, the first principal component (PC1) was signifi-
cantly associated with mortality (P  =  .003; Figure  4A–B). 
After all samples were arranged by their value on PC1, an 
immunological signature associated with mortality was 
revealed (Figure  4C), characterized by increased production 
of cytokines in unstimulated conditions and impaired produc-
tion of proinflammatory cytokines in response to all antigen 
stimuli.
Figure 2. Death hazard ratios for intra- and extracellular cytokines. A, Adjusted 
hazard ratios (aHR) for monocyte activation and intracellular cytokines measured in 
monocytes and neutrophils. Monocyte responses are in red; neutrophil responses 
are in yellow. *per 1% increase; ** per 10% increase; *** per 10 6/L increase; 
**** per 0.1% increase. B, The aHRs for the extracellular cytokines measured. HRs 
are per log2 pg/mL increase. Shown in red are proinflammatory cytokines mainly 
produced by monocytes; in yellow are proinflammatory cytokines mainly related to 
neutrophil function; in purple are pro-inflammatory cytokines related to T helper 1 
function; in green are antiinflammatory cytokines; in dark blue are growth factors. 
All HRs are adjusted for age, sex, CD4 count, HIV viral load, antiretroviral therapy 
status, and plate number, where applicable. q values are shown on the left; signif-
icant associations are in bold. Abbreviations: CSF, colony-stimulating factor; IFN, 
interferon; IL, interleukin; LPS, lipopolysaccharide; TNF, tumour necrosis factor; US, 
unstimulated.
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Mtb Mycobacteremia Is Associated With Cytopenia but Not With Sepsis 
Severity
Mycobacteremic patients had lower platelet (median 203 vs 
311 × 109/L), lymphocyte (median 0.42 vs 0.66 × 109/L), and 
monocyte counts (median 0.25 vs 0.42  ×  109/L) compared 
with non-mycobacteremic patients (P  =  .05, P  =  .0003, and 
P  =  .03, respectively). There were no differences in plasma 
concentrations of procalcitonin or lactate, percentages of 
CD16+CD14+ monocytes in unstimulated samples, or per-
centages of IL-6+ or TNF-α+ monocytes in response to stim-
ulations (Supplementary Figure 3). Mycobacteremic patients 
had lower absolute counts of IL-6+ monocytes compared with 
non-mycobacteremic tuberculosis patients in unstimulated 
samples and lower absolute counts of both IL-6+ and TNF-
α+ monocytes in response to LPS (Supplementary Figure 3). 
There were no differences in supernatant cytokine concen-
trations (Supplementary Table 4). None of the variables were 
associated with mycobacterial load, expressed in days to blood 
culture positivity (results not shown).
No Reversal of Immune Deficits With IFN-ɣ Costimulation
There were no differences in neutrophil and monocyte capacity 
to produce IL-6 or TNF-ɑ, nor in the concentration of any of 
the extracellular cytokines, when the LPS with IFN-ɣ costimu-
lation was compared with LPS only.
DISCUSSION
In HIV-infected patients diagnosed while in the hospital 
with microbiologically proven drug-susceptible tuberculosis, 
12-week mortality was 27%. More than half of patients had 
mycobacteremia; however, this was not associated with mortal-
ity. Patients who died had an immune phenotype characterized 
by higher concentrations of proinflammatory cytokines (CSF-3, 
TNF-ɑ, and IL-6) and antiinflammatory IL-1RA, an increased 
proportion of proinflammatory CD14+CD16+ monocytes, and 
impaired capacity of innate cells to produce proinflammatory 
cytokines in response to bacterial antigen stimuli.
Increased concentrations of proinflammatory cytokines CSF-
3, IL-6, and TNF-ɑ in unstimulated samples were associated with 
mortality. These cytokines are mainly produced by innate cells, 
suggesting a more activated state of the innate immune system 
in patients who die. This is consistent with results from other 
studies of mortality in HIV-associated tuberculosis [14], ART-
naive patients who start ART [17], and bacterial sepsis in HIV-
infected patients [18, 19]. There are several plausible explanations 
for this association. It is possible that immune activation reflects 
more disseminated tuberculosis. Another possible explanation 
is a causal relation: higher concentrations of proinflammatory 
cytokines led to increased tissue damage, organ failure, and 
immune exhaustion, impairing host defense to other pathogens.
Figure 3. Time to death and innate responses to Streptococcus pneumonia. Kaplan-Meier curves for the survival analysis of monocyte (n = 31) and neutrophil (n = 37) 
production of interleukin-6 and tumor necrosis factor-ɑ in response to S. pneumoniae are shown. The population of patients with human immunodeficiency virus–associated 
tuberculosis was split at the median for each respective analysis. Blue lines are for the group with cytokine production above the median; in red, the patients who had 
responses below the median. Abbreviations: IL, interleukin; TNF, tumour necrosis factor.
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Increased percentages of CD16+CD14+ monocytes were 
associated with mortality. This activated monocyte subset gen-
erally produces higher amounts of proinflammatory cytokines 
and is more phagocytic compared with the classic CD16 subset 
[20]. However, previous studies have shown that monocyte 
functionality may be impaired in active tuberculosis, with 
CD16+CD14+ monocytes refractory to dendritic cell matura-
tion, leading to impaired antigen presentation and decreased 
Figure 4. Principal component analysis. A, Values for principal component 1 (PC1) for patients with human immunodeficiency virus–associated tuberculosis who died vs 
those who survived; patients who died had significantly higher values for PC1. B, Loadings of respective variables on PC1; variables significantly associated with clinical out-
come are red. Variables significantly associated with clinical outcome (Mann-Whitney U test q < .10 and P < .05) tend to have high loadings, hence, contribute strongly to PC1. 
C, Heat map showing variables associated significantly with mortality in principal component analysis. Survivors are shown in blue, nonsurvivors in red. Increased production 
of proinflammatory cytokines in unstimulated samples appeared to be associated with mortality, as well as impaired production of proinflammatory cytokines in response 
to all antigen stimuli used. Abbreviations: CSF-3, CSF-2, colony-stimulating factor; IL, interleukin; LPS, lipopolysaccharide; Mtb, heat-killed Mycobacterium tuberculosis; S. 
pneumoniae, Streptococcus pneumoniae; TNF, tumour necrosis factor; US, unstimulated.
 • CID 2017:65 (1 July) • 81Innate Immunity and Mortality in HIV-Tuberculosis
secretion of IL-1β and IL-12 [21, 22]. Impaired phagocytic 
and antigen-presenting capacity of CD14+CD16+ cells has 
also been described in bacterial sepsis. Monocyte deactivation, 
with reduced production of TNF-ɑ in response to LPS was 
associated with fatal outcome [10, 23]. Our findings indicate 
that expansion of the CD16+ CD14+ monocyte population is 
observed together with impaired total monocyte and neutro-
phil responses to bacterial antigens in patients who die, poten-
tially contributing to mortality.
The immunological phenotype associated with mortality is 
similar to what has been described in bacterial sepsis. In bacte-
rial sepsis, time to intravenous broad-spectrum antibiotic treat-
ment is associated inversely with survival [9]. We did not find 
such an association for time to tuberculosis treatment. Although 
a potential association might have been masked by the lack of 
exact data on time of tuberculosis treatment initiation in hours, 
a more likely explanation is the fact that tuberculosis treatment 
is administered orally, and drug absorption might be hampered 
by intestinal tissue damage by tuberculosis or HIV.
Although invasive pneumococcal disease is one of the 
most frequent and lethal bacterial infections in HIV-infected 
patients, most studies focus on LPS responses. Interestingly, 
we found that impaired responses to S. pneumoniae were also 
strongly associated with mortality, indicating defects in host 
defense to this pathogen.
Reduced proinflammatory responses of innate cells to LPS 
and S.  pneumoniae in HIV-tuberculosis patients, compared 
with controls, suggest that tuberculosis has an immunosuppres-
sive effect that is additive to HIV. CD4 count and HIV viral load 
were not associated with mortality, whereas the innate immune 
features were independently associated.
Tuberculosis mycobacteremia was neither associated with 
mortality nor with more severe derangement of sepsis biomark-
ers. Mycobacteremia was associated with cytopenia, but there 
were no functional differences of innate cells. Previous studies 
have shown that in hospitalized febrile patients, mycobacter-
emia was associated with mortality [5, 6, 24], whereas in other 
studies among HIV-tuberculosis patients with mycobacteremia, 
it was not [7, 8]. Our findings illustrate that patients with severe 
HIV-tuberculosis can develop features of a sepsis syndrome 
even when mycobacterial blood cultures are negative.
There is increasing interest in host-directed immunotherapies 
for tuberculosis [25]. Recombinant IFN-ɣ has been shown to be 
beneficial in the treatment of cryptococcal meningitis [26] and 
other fungal infections [27], and a trial to investigate its applica-
tion for bacterial sepsis is ongoing [28]. We found no effect of ex 
vivo costimulation with recombinant IFN-ɣ in restoring mono-
cyte responses to LPS. Although ex vivo data cannot be directly 
extrapolated to in vivo conditions, our findings do not support 
investigation of recombinant IFN-ɣ as a potential immunother-
apy in this patient subset. Our data are supported by 2 clini-
cal trials [25, 29] that showed no beneficial effects of IFN-ɣ on 
sputum culture conversion in drug-sensitive or drug-resistant 
pulmonary tuberculosis. CSF-3 was investigated as adjunctive 
immune therapy for bacterial sepsis, but there was no signif-
icant survival benefit [30]. Our data of increased, rather than 
decreased, concentrations of CSF-3 in patients who die do not 
support investigation of CSF-3 for host-directed therapy in 
HIV-tuberculosis.
The early mortality [2] and prevalence of mycobacteremia [6, 
7, 24] reported here are similar to that found in studies from 
Africa and suggest our immunological findings are generaliza-
ble to other settings with a high tuberculosis and HIV burden. 
Limitations of our study include a limited number of bacterial 
blood cultures and lack of post-mortem examinations. Due 
to the strategy of treating patients with sepsis syndrome with 
broad-spectrum antibiotics at primary care referral centers 
upon referral to the hospital, only 47% of patients had bacterial 
blood cultures performed prior to receipt of antibiotics. Post-
mortem examinations were planned; however, in this study, 
none of the families agreed to this. Ex vivo markers of immune 
exhaustion were not measured, and this should be the subject 
of future studies.
Major strengths of our study are the variety of antigens/
organisms used for stimulations, enabling in vitro simulation 
of gram-negative, gram-positive, and mycobacterial infec-
tions. The inclusion of an HIV-infected control group with-
out active tuberculosis and the exclusion of patients without 
microbiologically confirmed tuberculosis facilitate conclusions 
on the associations of findings with severe tuberculosis specif-
ically, minimizing misclassification bias of other diagnoses or 
advanced HIV alone.
Our study has several implications for clinical care and 
future research. The immune profile observed in HIV-
tuberculosis patients, particularly those who died, suggests 
that disseminated tuberculosis in the context of advanced 
HIV infection can significantly impair host innate responses 
to bacteria, possibly resulting in an immunological predispo-
sition to bacterial superinfections [3, 4]. This study adds to 
our understanding of immunopathology in HIV-tuberculosis. 
By focusing on patients who required hospital admission 
and innate immune changes, we confirmed that the high 
mortality in this patient subset is associated with an immu-
nological phenotype similar to bacterial sepsis. Immune 
activation, with higher concentrations of proinflammatory 
cytokines and expansion of the CD16+CD14+ monocyte 
population, is potentially leading to increased tissue damage. 
Simultaneously, there is impairment of innate immune func-
tional responses, with reduced production of proinflamma-
tory cytokines in response to antigens of bacterial pathogens. 
In the future, immunomodulatory interventions that have 
proven beneficial in bacterial sepsis should also be evaluated 
for patients with severe HIV-tuberculosis.
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Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the authors to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the authors, 
so questions or comments should be addressed to the corresponding 
author.
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